163 related articles for article (PubMed ID: 26215730)
1. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma.
Chen N; Ren M; Li R; Deng X; Li Y; Yan K; Xiao L; Yang Y; Wang L; Luo M; Fay WP; Wu J
Mol Cancer; 2015 Jul; 14():140. PubMed ID: 26215730
[TBL] [Abstract][Full Text] [Related]
2. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
3. Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis.
Belghasem M; Roth D; Richards S; Napolene MA; Walker J; Yin W; Arinze N; Lyle C; Spencer C; Francis JM; Thompson C; Andry C; Whelan SA; Lee N; Ravid K; Chitalia VC
Blood; 2019 Dec; 134(26):2399-2413. PubMed ID: 31877217
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
[TBL] [Abstract][Full Text] [Related]
5. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells.
Kang J; Kim W; Kwon T; Youn H; Kim JS; Youn B
Oncotarget; 2016 Apr; 7(17):23961-74. PubMed ID: 27004408
[TBL] [Abstract][Full Text] [Related]
7. [Effects of bevacizumab and cisplatin on human lung adenocarcinoma A549/DDP xenografts in nude mice].
Dai M; Luo RC; Zheng DY; Lü CW; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1402-5. PubMed ID: 17884788
[TBL] [Abstract][Full Text] [Related]
8. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
9. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.
Ramer R; Rohde A; Merkord J; Rohde H; Hinz B
Pharm Res; 2010 Oct; 27(10):2162-74. PubMed ID: 20668920
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Hisada Y; Garratt KB; Maqsood A; Grover SP; Kawano T; Cooley BC; Erlich J; Moik F; Flick MJ; Pabinger I; Mackman N; Ay C
Blood Adv; 2021 Jan; 5(2):487-495. PubMed ID: 33496742
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Liu W; Xu J; Wang M; Wang Q; Bi Y; Han M
Int J Oncol; 2011 Nov; 39(5):1213-20. PubMed ID: 21785819
[TBL] [Abstract][Full Text] [Related]
13. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.
Watanabe M; Boyer JL; Crystal RG
Gene Ther; 2010 Aug; 17(8):1042-51. PubMed ID: 20596059
[TBL] [Abstract][Full Text] [Related]
14. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage.
Zhu C; Shen H; Zhu L; Zhao F; Shu Y
Cell Physiol Biochem; 2017; 44(6):2201-2211. PubMed ID: 29253845
[TBL] [Abstract][Full Text] [Related]
16. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
[No Abstract] [Full Text] [Related]
17. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
19. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
